Evidence map›Paper›PMID 36157436›Full record

ArticleFrontiers in endocrinology2022

Effects of scoparone on non-alcoholic fatty liver disease revealed by RNA sequencing.

Xiaoyan Huang, Ya Gao, Houkang Cao, Jun Li, Siyi Mo, Ting Li, Jianzhao Wu, Kai Guo, Riming Wei, Kefeng Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026
    Article
  3. Foods (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoyan HuangPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Ya GaoPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Houkang CaoPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Jun LiDepartment of Obstetrics & Gynaecology, National University of Singapore, Singapore, Singapore.
Siyi MoPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Ting LiPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Jianzhao WuPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Kai GuoPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Riming WeiPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.
Kefeng ZhangPharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scoparone (SCO) is known to have curative effect of alleviating liver injury. The purpose of this study was to observe the therapeutic effect and possible mechanism of SCO against high-fat diet (HFD) induced non-alcoholic liver disease (NAFLD) through

Indexed as

Non-alcoholic Fatty Liver DiseaseAnimalsCoumarinsFatty AcidsMaleMiceSequence Analysis, RNATransaminasesTriglyceridesCoumarinsFatty AcidsscoparoneTransaminasesTriglyceridescholesterol metabolismfatty acid (triglyceride) metabolismnon-alcoholic liver disease (NAFLD)ribonucleic Acid (RNA) sequencingscoparone

Identifiers

PMID36157436
PMCPMC9500212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.